First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

BACKGROUND: MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid cystic carcinoma (AdCC). Therefore, the MYB protein is an ideal target to vaccinate against to aid recruitment of tumour infiltrating lymphocytes (TILs) against these tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Toan, Pereira, Lloyd, Roth, Sara, Galletta, Laura, Link, Emma, Akhurst, Tim, Solomon, Ben, Michael, Michael, Darcy, Phillip, Sampurno, Shienny, Heriot, Alexander, Ramsay, Robert, Desai, Jayesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804811/
https://www.ncbi.nlm.nih.gov/pubmed/31650066
http://dx.doi.org/10.1016/j.conctc.2019.100409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804811/
https://www.ncbi.nlm.nih.gov/pubmed/31650066
http://dx.doi.org/10.1016/j.conctc.2019.100409

Ejemplares similares